Market Closed -
Nasdaq
01:30:00 27/04/2024 am IST
|
5-day change
|
1st Jan Change
|
2.27
USD
|
-3.40%
|
|
-5.42%
|
-24.58%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
541.3
|
274.4
|
166
|
125.2
|
-
|
-
|
Enterprise Value (EV)
1 |
335.8
|
169.6
|
166
|
102.4
|
-24.32
|
-105.8
|
P/E ratio
|
-3.71
x
|
-2.67
x
|
-1.67
x
|
-1.84
x
|
-1.83
x
|
-1.82
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3,759
x
|
132
x
|
53.6
x
|
37.1
x
|
157
x
|
4.63
x
|
EV / Revenue
|
2,332
x
|
81.8
x
|
53.6
x
|
30.4
x
|
-30.4
x
|
-3.91
x
|
EV / EBITDA
|
-5.2
x
|
-1.68
x
|
-
|
-1.08
x
|
0.16
x
|
0.7
x
|
EV / FCF
|
-5.68
x
|
-1.7
x
|
-
|
-1.11
x
|
0.3
x
|
0.93
x
|
FCF Yield
|
-17.6%
|
-58.9%
|
-
|
-89.8%
|
337%
|
108%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
47,775
|
48,049
|
55,142
|
55,155
|
-
|
-
|
Reference price
2 |
11.33
|
5.710
|
3.010
|
2.270
|
2.270
|
2.270
|
Announcement Date
|
10/03/22
|
01/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.144
|
2.073
|
3.094
|
3.371
|
0.8
|
27.05
|
EBITDA
1 |
-
|
-64.64
|
-101.2
|
-
|
-94.9
|
-152
|
-150.2
|
EBIT
1 |
-
|
-66.03
|
-102.8
|
-100.3
|
-82.93
|
-113.9
|
-156.8
|
Operating Margin
|
-
|
-45,855.56%
|
-4,957.36%
|
-3,240.5%
|
-2,459.86%
|
-14,239.65%
|
-579.8%
|
Earnings before Tax (EBT)
1 |
-
|
-68.28
|
-102.7
|
-97.43
|
-74.1
|
-91.65
|
-132.9
|
Net income
1 |
-29.45
|
-68.28
|
-102.7
|
-97.43
|
-74.1
|
-91.65
|
-132.9
|
Net margin
|
-
|
-47,416.67%
|
-4,954.22%
|
-3,148.93%
|
-2,197.79%
|
-11,456.69%
|
-491.23%
|
EPS
2 |
-7.556
|
-3.050
|
-2.140
|
-1.800
|
-1.232
|
-1.240
|
-1.245
|
Free Cash Flow
1 |
-
|
-59.08
|
-99.9
|
-
|
-92
|
-82
|
-114
|
FCF margin
|
-
|
-41,025%
|
-4,818.86%
|
-
|
-2,728.81%
|
-10,250%
|
-421.49%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/07/21
|
10/03/22
|
01/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
0.144
|
0.268
|
0.476
|
0.595
|
0.735
|
0.516
|
0.759
|
0.831
|
0.989
|
1.164
|
1.164
|
0.5214
|
0.5214
|
0.5
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-17.22
|
-20.66
|
-19.96
|
-25.85
|
-25.98
|
-30.97
|
-25.82
|
-30.84
|
-22.9
|
-20.7
|
-20.55
|
-20.45
|
-20.65
|
-21.31
|
-14
|
Operating Margin
|
-
|
-14,350%
|
-7,447.39%
|
-5,431.51%
|
-4,367.23%
|
-4,213.2%
|
-5,003.49%
|
-4,063.24%
|
-2,756.08%
|
-2,092.92%
|
-1,765.38%
|
-1,756.11%
|
-3,959.5%
|
-4,086.15%
|
-2,800%
|
Earnings before Tax (EBT)
1 |
-18.53
|
-20.85
|
-20.16
|
-25.91
|
-25.8
|
-30.83
|
-25.28
|
-29.69
|
-22.25
|
-20.21
|
-19.56
|
-18.54
|
-18.21
|
-17.63
|
-14
|
Net income
1 |
-18.53
|
-20.85
|
-20.16
|
-25.91
|
-25.8
|
-30.83
|
-25.28
|
-29.69
|
-22.25
|
-20.21
|
-19.56
|
-18.54
|
-18.21
|
-17.63
|
-14
|
Net margin
|
-
|
-14,481.94%
|
-7,523.88%
|
-5,443.7%
|
-4,335.97%
|
-4,194.01%
|
-4,899.03%
|
-3,911.33%
|
-2,677.26%
|
-2,043.88%
|
-1,680.34%
|
-1,592.3%
|
-3,492.46%
|
-3,381.66%
|
-2,800%
|
EPS
2 |
-0.5700
|
-0.4400
|
-0.4200
|
-0.5400
|
-0.5400
|
-0.6400
|
-0.5000
|
-0.5400
|
-0.4000
|
-0.3700
|
-0.3600
|
-0.3280
|
-0.2940
|
-0.2640
|
-0.2500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/11/21
|
10/03/22
|
04/05/22
|
04/08/22
|
08/11/22
|
01/03/23
|
04/05/23
|
03/08/23
|
09/11/23
|
28/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
205
|
105
|
-
|
22.8
|
150
|
231
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-59.1
|
-99.9
|
-
|
-92
|
-82
|
-114
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
1.38
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
66.57%
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/07/21
|
10/03/22
|
01/03/23
|
28/03/24
|
-
|
-
|
-
|
Last Close Price
2.27
USD Average target price
11
USD Spread / Average Target +384.58% Consensus |
1st Jan change
|
Capi.
|
---|
| -24.58% | 125M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|